AU2022337286A1 - Bispecific binding proteins that bind cd137 and a tumor associated antigen - Google Patents

Bispecific binding proteins that bind cd137 and a tumor associated antigen Download PDF

Info

Publication number
AU2022337286A1
AU2022337286A1 AU2022337286A AU2022337286A AU2022337286A1 AU 2022337286 A1 AU2022337286 A1 AU 2022337286A1 AU 2022337286 A AU2022337286 A AU 2022337286A AU 2022337286 A AU2022337286 A AU 2022337286A AU 2022337286 A1 AU2022337286 A1 AU 2022337286A1
Authority
AU
Australia
Prior art keywords
seq
binding
variable region
binding protein
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022337286A
Other languages
English (en)
Inventor
Chang Hung Chen
Haichun Huang
Ming Lei
Han Li
Yick LOI
Yi Pei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novarock Biotherapeutics Ltd
Original Assignee
Novarock Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novarock Biotherapeutics Ltd filed Critical Novarock Biotherapeutics Ltd
Publication of AU2022337286A1 publication Critical patent/AU2022337286A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2022337286A 2021-09-03 2022-09-01 Bispecific binding proteins that bind cd137 and a tumor associated antigen Pending AU2022337286A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163240402P 2021-09-03 2021-09-03
US63/240,402 2021-09-03
US202263327700P 2022-04-05 2022-04-05
US63/327,700 2022-04-05
PCT/US2022/075846 WO2023034922A2 (en) 2021-09-03 2022-09-01 Bispecific binding proteins that bind cd137 and a tumor associated antigen

Publications (1)

Publication Number Publication Date
AU2022337286A1 true AU2022337286A1 (en) 2024-02-29

Family

ID=85413134

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022337286A Pending AU2022337286A1 (en) 2021-09-03 2022-09-01 Bispecific binding proteins that bind cd137 and a tumor associated antigen

Country Status (7)

Country Link
US (1) US20240383978A1 (https=)
EP (1) EP4395823A4 (https=)
JP (1) JP2024532485A (https=)
KR (1) KR20240073008A (https=)
AU (1) AU2022337286A1 (https=)
CA (1) CA3230426A1 (https=)
WO (1) WO2023034922A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240133746A (ko) * 2022-01-09 2024-09-04 아이-맵 바이오파마 컴파니 리미티드 다중특이적 작제물 및 이의 용도
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564432A1 (en) * 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
EP2303924B1 (en) * 2008-06-16 2016-07-27 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
PT3514172T (pt) * 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
EP3554544A4 (en) * 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US20220177583A1 (en) * 2019-03-20 2022-06-09 The Regents Of The University Of California Claudin-6 bispecific antibodies
BR112021008870A2 (pt) * 2019-08-12 2021-11-30 Abl Bio Inc Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.
AU2020337958A1 (en) * 2019-08-28 2022-03-17 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
JP7758672B2 (ja) * 2019-12-20 2025-10-22 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
CA3174094A1 (en) * 2020-03-31 2021-10-07 Shinya Ishii Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
US20250277026A1 (en) * 2021-03-02 2025-09-04 Novarock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof

Also Published As

Publication number Publication date
JP2024532485A (ja) 2024-09-05
CA3230426A1 (en) 2023-03-09
EP4395823A4 (en) 2025-07-16
US20240383978A1 (en) 2024-11-21
EP4395823A2 (en) 2024-07-10
WO2023034922A2 (en) 2023-03-09
KR20240073008A (ko) 2024-05-24
WO2023034922A3 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
US20240383978A1 (en) Bispecific binding proteins that bind cd137 and a tumor associated antigen
AU2019264965B2 (en) Antibodies specific to human Nectin4
US20230272063A1 (en) Anti-claudin 18 antibodies and methods of use thereof
JP6432121B2 (ja) Ｐｄｌ−１抗体、その医薬組成物及びその使用
JP2024125370A (ja) クローディン１８．２結合部分およびその利用
KR20220148175A (ko) Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
JP2024109799A (ja) ５ｔ４シングルドメイン抗体およびその治療組成物
JP2022504822A (ja) Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
EP4273170A1 (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
US20250277026A1 (en) Antibodies against claudin-6 and uses thereof
US20240067740A1 (en) Antibodies to tnfr2 and uses thereof
JP2022505144A (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
CN118234511A (zh) 与cd137和肿瘤相关抗原结合的双特异性结合蛋白
US20250002599A1 (en) Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf-beta and uses thereof
HK40112412A (zh) 与cd137和肿瘤相关抗原结合的双特异性结合蛋白
US20260078179A1 (en) Cdh17 antibodies and uses thereof
AU2020217012B2 (en) Anti-claudin 18 antibodies and methods of use thereof
HK40100877A (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
WO2024199364A1 (zh) 抗lag3抗体、药物组合物及用途
HK40112413A (zh) 与PD-L1、CD137和/或TGFβ的双特异性和三特异性结合蛋白及其用途